# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Morgan Stanley analyst Vikram Purohit maintains Acelyrin (NASDAQ:SLRN) with a Equal-Weight and lowers the price target from ...
HC Wainwright & Co. analyst Emily Bodnar downgrades Acelyrin (NASDAQ:SLRN) from Buy to Neutral and lowers the price targ...
Acelyrin reports promising Phase 3 results for izokibep in hidradenitis suppurativa, announces a strategic focus on lonigutamab.
Piper Sandler analyst Yasmeen Rahimi maintains Acelyrin (NASDAQ:SLRN) with a Overweight and lowers the price target from $68...
Acelyrin (NASDAQ:SLRN) reported quarterly losses of $(0.86) per share which missed the analyst consensus estimate of $(0.69) by...